Zhao Hongfu
Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, No. 126, Xiantai Street, Changchun, 130033, Jilin, China.
Discov Oncol. 2025 May 6;16(1):678. doi: 10.1007/s12672-025-02487-2.
INTRODUCTION/BACKGROUND: Malignant tumors pose a serious threat to human health. As tumor volume increases, conventional external beam radiation therapy (cEBRT) faces challenges in tumor control and normal tissue toxicity. Spatially fractionated radiation therapy (SFRT) has emerged as an alternative approach.
This article reviews the history of SFRT, including kilovolt X-ray based GRID, megavolt X-ray based GRID, MLC-shaped GRID, LATTICE radiation therapy (LRT), Bragg-peak based SFRT, microbeam, minibeam, SBRT-PATHY, and ISPART. It also explores its radiobiological mechanisms, such as immunomodulation, bystander and abscopal effects, and vascular response. Clinical studies of SFRT in palliative tumor treatment are summarized, and its limitations and future directions are discussed.
SFRT has shown high symptom remission rates, significant target volume reduction, and even tumor control and long-term survival in some cases across various tumor types. However, it has limitations like lack of standardized dosimetric parameters, complex implementation, small-scale clinical studies, and uncertain immunomodulatory potential.
Despite limitations, SFRT shows promise as a palliative radiation therapy technique. Future large-scale, multi-center clinical trials are needed to standardize dosimetric parameters, clarify immunomodulatory mechanisms, and simplify the technology for wider application.
引言/背景:恶性肿瘤对人类健康构成严重威胁。随着肿瘤体积增大,传统外照射放疗(cEBRT)在肿瘤控制和正常组织毒性方面面临挑战。空间分割放疗(SFRT)已成为一种替代方法。
本文回顾了SFRT的历史,包括基于千伏X射线的格栅放疗、基于兆伏X射线的格栅放疗、多叶准直器形状的格栅放疗、点阵放疗(LRT)、基于布拉格峰的SFRT、微束、迷你束、立体定向体部放疗路径(SBRT-PATHY)和智能分割放疗(ISPART)。还探讨了其放射生物学机制,如免疫调节、旁观者效应和远隔效应以及血管反应。总结了SFRT在姑息性肿瘤治疗中的临床研究,并讨论了其局限性和未来方向。
SFRT在各种肿瘤类型中均显示出较高的症状缓解率、显著的靶体积缩小,甚至在某些情况下实现了肿瘤控制和长期生存。然而,它存在一些局限性,如缺乏标准化的剂量学参数、实施复杂、临床研究规模小以及免疫调节潜力不确定。
尽管存在局限性,但SFRT作为一种姑息性放疗技术显示出前景。未来需要进行大规模、多中心临床试验,以标准化剂量学参数、阐明免疫调节机制并简化技术以实现更广泛应用。